The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's submission has become effective as of May 2, 2024. The submission, identified by Accession Number 0001214659-24-007806 and File Number 333-240984, was a post-effective amendment (POS AM) to a previously filed registration statement. This notice of effectiveness indicates that the SEC has reviewed and accepted the company's submission, allowing Biodexa Pharmaceuticals to proceed with the actions outlined in the amendment.

The United States Securities and Exchange Commission (SEC) has declared that Biodexa Pharmaceuticals Plc's submission has become effective as of May 2, 2024. The submission, identified by Accession Number 0001214659-24-007806 and File Number 333-240984, was a post-effective amendment (POS AM) to a previously filed registration statement. This notice of effectiveness indicates that the SEC has reviewed and accepted the company's submission, allowing Biodexa Pharmaceuticals to proceed with the actions outlined in the amendment.